Theravance Biopharma Inc (TBPH) News
Follow Theravance Biopharma Inc (TBPH) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 8 public stories across 3 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
H
Theravance Biopharma Announced Transfer or Voluntary Withdrawal of Listing
On September 23, 2026, the company notified Nasdaq of the merger closing and requested suspension of trading as of the close of business that day, and that Nasdaq file a Form 25 to delist and deregister its ordinary shar
MNA | Sep 23, 2026, 08:48 PM UTC
H
Theravance Biopharma CEO Rick E Winningham resigns; Kristin Stafford, Scott Platshon and Paul Schneider named directors
Theravance Biopharma announced that CEO Rick E Winningham and five directors resigned in connection with a merger, and Kristin Stafford, Scott Platshon and Paul Schneider became directors.Original SEC Filing: Theravance
MNA | Sep 23, 2026, 08:48 PM UTC
H
Theravance Biopharma to Be Acquired by Zymeworks for $17 Per Share Plus CVR
Theravance Biopharma completed a merger with Zymeworks, delivering $17.00 in cash per share plus one contingent value right (CVR) to shareholders and taking the company private. In connection with the deal, a CVR framewo
MNA | Sep 23, 2026, 08:48 PM UTC
L
Zymeworks Completes Acquisition of Theravance Biopharma
VANCOUVER, British Columbia, Sept. 23, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. NASDAQ:ZYME, a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipeline of novel, multifu
MNA | Sep 23, 2026, 08:02 PM UTC
L
Theravance facing several lawsuits seeking to block Zymeworks acquisition
Content provided by Seeking Alpha is intended for information purposes only, and that Seeking Alpha does not offer any personalist investment advice and is not a licensed securities dealer, broker, US investment adviser
MNA | Sep 10, 2026, 03:11 PM UTC
M
Theravance Bi supplements proxy in Zymeworks merger, faces suits
Theravance Biopharma said it added supplemental disclosures to its proxy in connection with the proposed merger with Zymeworks. It also confirmed three shareholder complaints tied to the deal.
MNA | Sep 10, 2026, 01:14 PM UTC
M
Theravance Biopharma Discloses Termination Fee Of $32.5M After Acquisition Offer By Zymeworks
The Merger Agreement contains certain customary termination rights for the Company and Parent. Subject to the terms and conditions of the Merger Agreement, the Company or Parent may terminate the Merger Agreement if the
MNA | Jun 29, 2026, 10:43 AM UTC
H
Zymeworks To Acquire Theravance Biopharma At $17 Per Share For Total Cash Consideration Of $929M
Acquisition adds YUPELRI® (revefenacin), the first and only approved nebulized long-acting muscarinic antagonist (LAMA) for the maintenance treatment of COPD to Zymeworks' portfolio Acquisition of Theravance Biopharma at
EARNINGS | Jun 29, 2026, 10:04 AM UTC